CPX-351 Plus Ivosidenib

Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
30 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Chemotherapy, Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
Trial Type
Treatment
Last Update
10 months ago
SparkCures ID
1557
NCT Identifier
NCT04493164

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.